The vitamin D 3 receptor (VDR) is a ligand dependent transcription factor implicated in regulation of cell cycle, differentiation and apoptosis of both normal and transformed cells derived from mammary gland. In these studies, we examined whether VDR status altered mammary gland morphology or transformation in the well characterized MMTV-neu transgenic model of breast cancer. We demonstrate that VDR protein is highly expressed in neu-positive epithelial cells of pre-neoplastic lesions, established tumors and lung metastases from MMTV-neu mice. Furthermore, MMTVneu mice lacking VDR exhibit abnormal mammary ductal morphology characterized by dilated, distended ducts containing dysplastic epithelial cells. From 12 months of age on, MMTV-neu mice lacking VDR also experience body weight loss, atrophy of the mammary fat pad, estrogen deficiency and reduced survival. The limited survival of MMTV-neu mice lacking VDR precluded an accurate assessment of the impact of complete VDR ablation on tumor development. MMTV-neu mice heterozygous for the VDR, however, did not exhibit body weight loss, mammary gland atrophy or compromised survival. Compared to MMTV-neu mice with two copies of the VDR gene, haploinsufficiency of VDR shortened the latency and increased the incidence of mammary tumor formation. Tumor histology and expression/subcellular localization of the neu transgene were not altered by VDR haploinsufficiency despite a significant decrease in tumor VDR expression. Collectively, these studies suggest that VDR gene dosage impacts on age related changes in ductal morphology and oncogene induced tumorigenesis of the mammary gland in vivo.
INTRODUCTION
The biologically active form of vitamin D, 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) modulates differentiation, cell cycle and apoptosis of stromal and epithelial cells derived from mammary gland and breast cancers (1) (2) (3) (4) . Cell cycle arrest induced by 1,25(OH) 2 D 3 is associated with inhibition of signaling by growth factors such as IGF and EGF (5, 6) and up-regulation of the cyclin-dependent kinase inhibitors p21 (7) and p27 (8) . Furthermore, 1,25(OH) 2 D 3 inhibits growth of both estrogen-dependent and estrogen-independent tumor cells (2, (9) (10) (11) (12) . The effects of 1,25(OH) 2 D 3 are mediated by the vitamin D receptor (VDR), a nuclear receptor present in over 80% of human breast cancers (13, 14) . In previous studies, we demonstrated the presence of VDR in normal murine mammary gland and reported accelerated mammary gland development during puberty and pregnancy in VDR knockout (-/-) mice (15, 16) . Furthermore, postlactational involution, a process driven by apoptosis of the mammary epithelial cells, is delayed in VDR-/-mice (16) . These studies have demonstrated that 1,25(OH) 2 D 3 and the VDR participate in negative growth regulation of the mammary gland.
In addition to effects of 1,25(OH) 2 D 3 and the VDR on normal mammary gland development, evidence supports a role for vitamin D 3 signaling in protection against breast cancer development. 1,25(OH) 2 D 3 inhibits carcinogen induced pre-neoplastic lesions in vitro (17) and dietary vitamin D 3 negates the effects of dietary fat and chemical carcinogens on mammary tumorigenesis in vivo (18, 19) . Furthermore, treatment with synthetic VDR agonists can prevent the development of carcinogen induced mammary tumors (20, 21) . Data from two large epidemiological studies indicate that optimal vitamin D 3 nutrition affords protection against breast cancer (22, 23) , and low serum 1,25(OH) 2 D 3 has been correlated with increased breast cancer risk and metastasis (24, 25) . Collectively, these studies suggest that vitamin D 3 signaling activates growth inhibitory pathways that may protect mammary cells from transformation.
In the studies presented here, we have directly tested the hypothesis that VDR signaling modulates mammary gland morphology and/or tumorigenesis in vivo. MMTVneu transgenic mice, an established murine model of breast cancer, were crossed with VDR-/-mice to generate MMTV-neu mice on VDR wild type (neu/VDR+/+), heterozygous (neu/VDR+/-), or knockout (neu/VDR-/-) backgrounds. MMTV-neu mice selectively express the c-neu proto-oncogene in the mammary gland and predictably develop estrogen independent mammary tumors (26) . The c-neu proto-oncogene encodes a member of the EGF receptor family that is amplified in approximately 30% of breast cancer patients and is associated with poor prognosis (27, 28) . Since 1,25(OH) 2 D 3 and VDR inhibit EGF receptor signaling (29) , we hypothesized that disruption of VDR signaling might accelerate tumorigenesis in MMTV-neu mice. In support of this hypothesis, we demonstrate that VDR is highly expressed in mammary tumors of MMTV-neu mice and that loss of one copy of the VDR accelerates neu-driven mammary tumorigenesis. Although body weight loss and decreased survival in neu/VDR-/-mice precluded assessment of tumor development, alveolar hyperplasia and dysplastic ductal epithelial cells were consistently observed in neu/VDR-/-females. These in vivo studies implicate VDR signaling in modulation of mammary gland function and tumorigenesis, and provide a mechanistic basis for numerous epidemiological and clinical observations linking breast cancer risk to vitamin D 3 status.
MATERIALS AND METHODS

Animal Maintenance.
Wild type (+/+) and VDR knockout (-/-) C57BL6 mice (originally provided by Dr. Marie Demay, Harvard Medical School, Boston, MA) were maintained as described by Zinser et al (15) . Male VDR-/-mice were crossed with female mice on the FVB background containing the neu proto-oncogene under the control of the MMTV 3' LTR promoter (MMTV-neu mice, line N202, Jackson Labs, Bar Harbor, ME) to produce an F 1 generation carrying the neu transgene and heterozygous (+/-) for VDR (neu/VDR+/-). F 1 females were subsequently crossed with F 1 males to produce the F 2 generation consisting of neu/VDR+/+, neu/VDR+/-and neu/VDR-/-animals. This strategy was modeled after studies in which the role of estrogen receptor α in MMTV-neu tumorigenesis was evaluated (30) . Of 512 male and female mice on the three VDR backgrounds that carried the neu transgene, 111 (22%) were wild-type (neu/VDR+/+), 272 were heterozygous (neu/VDR+/-) and 129 were homozygous null (neu/VDR-/-) for VDR. Thus, the F 2 generation mice had the expected Mendelian distribution of VDR genotypes.
To prevent disturbances in calcium homeostasis and hormonal imbalances in mice lacking VDR, all mice were fed a diet containing 2% calcium, 1.25% phosphorous, and 20% lactose with 2.2IU vitamin D/g (TD96348, Teklad, Madison, WI). This diet has been shown to support normal mineral and bone homeostasis in VDR-/-mice up to 10 weeks of age, including during pregnancy (16, (31) (32) (33) . All animal procedures were approved by the University of Notre Dame animal care and use committee.
Genotyping was achieved by PCR using DNA isolated from ear punches obtained at weaning. Punches were digested in lysis buffer (50mM Tris Base pH 8, 2mM NaCl, 10mM EDTA and 1% SDS), containing 20mg/ml Proteinase K, diluted in ddH 2 O, boiled, and allowed to cool. After purification, DNA was added to Ready-To-Go PCR beads (Amersham Pharmacia Biotech Inc., Piscataway, NJ) along with primers designed to detect a 500bp region of the neomyocin gene, a 752bp region of exon 3 of the VDR or a 700bp region of the neu transgene.
Survival and Tumor Development Curves.
Female mice (63 neu/VDR+/+, 144 neu/VDR+/-and 72 neu/VDR-/-) were examined weekly for mammary tumor development by palpation for up to 18.5 months. Mice that exhibited significant weight loss, morbidity or excessive tumor burden were euthanized, and samples were collected when possible as described below. Data on survival and tumor development were subjected to Kaplan-Meier analysis using GraphPad Prism for Windows, GraphPad Software, San Diego, CA, www.graphpad.com. Kaplan-Meier curves of survival data included mice that died or were euthanized due to tumor burden as well as mice that died from other causes.
At sacrifice, mammary glands, tumors, and lungs were removed for histological examination. Both abdominal fat stores and mammary gland fat pads were assessed for signs of atrophy. Tissues and tumors were fixed in 4% neutral buffered paraformaldehyde for histology and immunohistochemistry.
Whole mounting and detection of pre-neoplastic lesions.
For whole mount analysis, entire mammary glands were surgically removed, fixed in Carnoy's fixative, stained overnight in carmine alum, processed and mounted. For assessment of preneoplastic lesions and ductal morphology, twelve MMTV-neu mice of each VDR genotype were sacrificed at 10.5 months of age. Two thoracic and two inguinal glands from each mouse were prepared as whole mounts, and ductal architecture and pre-neoplastic lesions were assessed in all four glands by three investigators in a blinded fashion. Preneoplastic lesions (well circumscribed, latent tumors which were not palpable) were quantitated in mammary gland whole mounts examined on an Olympus SZX12 stereoscope at 10x. Data are expressed as the percentage of animals with one or more glands containing a preneoplastic lesion measuring at least 1mm 3 in diameter.
Histology and Immunohistochemistry.
Formalin fixed mammary glands and tumors were embedded in paraffin, sectioned at 5µm, and stained with H&E. Tissue sections were viewed on an Olympus AX70 microscope and photographed with the Spot RT Slider digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI). To detect VDR, formalin fixed paraffin embedded sections were incubated in 2 N HCl at 37° C for 20 minutes. After rinsing in PBS for 5 minutes, slides were incubated overnight with a rat monoclonal antibody directed against VDR (clone 9A7, Neomarkers, Fremont, CA) at a dilution of 1:60, followed by incubation with anti-rat secondary antibody at a dilution of 1:200. To detect neu proto-oncoprotein, a mouse monoclonal primary antibody (clone 3B5, NeoMarkers, Fremont, CA) was prepared at a dilution of 1:70 and was incubated using the M.O.M kit according to manufacturer's directions (Vector Laboratories, Burlingame, CA). For both VDR and neu, slides were counterstained with Harris modified hematoxylin and photographed.
Western Blotting.
Thoracic mammary glands or kidney (100mg) were homogenized in Laemlli buffer containing phosphatase and protease inhibitors (34) , separated by SDS-PAGE, transferred to nitrocellulose, blocked with 5% skim milk and immunoblotted with antibodies against VDR (clone C-20, Santa Cruz Biotech, Santa Cruz, CA) or c-neu (NCL-L-CBE-356, Vector Laboratories, Burlingame, CA).
After incubation with appropriate secondary antibody, blots were developed by enhanced chemiluminescence using products from Pierce.
Serum Hormone and Calcium Assay.
17β-estradiol radioimmunoassay was conducted with a reagent kit from DiaSorin (Stillwater, MN) and serum calcium was determined with a colorimetric assay kit (Sigma, St. Louis, MO) according to manufacturer's directions.
Quantitative Real Time PCR.
Total RNA was isolated from frozen mammary tumors (90-150mg) with Trizol reagent (GibcoBRL, Rockville, MD) and used for reverse transcription reactions using TaqMan Reverse Transcription Reagents (N808-0234, Applied Biosystems, Foster City, CA). Six independent samples were analyzed for each genotype, and reactions were performed in triplicate, generating three separate 1.5ug cDNA stocks/sample. Each of the triplicate cDNA stocks were then independently analyzed for VDR expression in duplicate by real time PCR using the TaqMan PCR Core Reagent Kit (N808-0228, Applied Biosystems, Foster City, CA) and specific primer and probe sets. Gene expression was normalized against 18s RNA and reported as normalized gene expression. For each genotype, duplicate values per run were averaged and triplicate runs were then averaged to generate one value for each animal. The final data is expressed as the mean ± standard error of six animals for each genotype.
RESULTS
VDR is expressed in MMTV-neu tumors and metastatic foci.
These studies were designed to test the hypothesis that VDR signaling modulates mammary gland morphology or tumorigenesis in the MMTV-neu mouse model. A direct effect of VDR on neu driven pathways in the mammary gland would be dependent on the presence of VDR in mammary lesions which develop in MMTV-neu mice. Previous studies have documented that VDR is present in normal murine mammary gland (15) (16) (17) , but no studies have reported VDR expression in genetically engineered murine models of mammary tumorigenesis. As demonstrated in Figure 1 , pre-neoplastic lesions, identified in mammary gland whole mounts of MMTV-neu mice ( Figure 1A ), express immunoreactive VDR protein ( Figure 1B) . Furthermore, epithelial tumor cells in established MMTV-neu tumors ( Figure 1C ) also express VDR ( Figure  1D ), and the percentage of cells that express VDR is higher in tumors than in normal mammary ducts (15, 16) . Expression of the VDR mRNA in MMTV-neu tumors was confirmed by quantitative real time PCR, and this analysis also confirmed higher VDR expression in tumors compared to normal mammary gland (not shown). MMTV-neu tumors can metastasize to the lung ( Figure 1E ), and VDR was also detected in pulmonary metastatic foci ( Figure 1F ). The presence of the VDR during all stages of neu-driven tumorigenesis suggests that the MMTV-neu mouse represents a suitable model system to test the hypothesis that VDR signaling modulates mammary tumor development or progression.
Effect of VDR status on mammary gland morphology in MMTV-neu mice.
Female virgin MMTV-neu mice with two (neu/VDR+/+), one (neu/VDR+/-) or no (neu/VDR-/-) copies of the VDR were used for comparison of mammary gland morphology and tumor development as a function of VDR status. Since mammary tumors in MMTV-neu mice on the C57BL6 background develop slowly (30, 35, 36) , we initially examined overall glandular morphology and pre-neoplastic lesions in a subset of healthy mice of each genotype at 10.5 months of age. Representative glandular morphology is presented in Figure 2 , with pathological findings summarized in Table I . The majority of glands from neu/VDR+/+ mice exhibited age appropriate glandular development -thin ducts with secondary and tertiary branching and minimal alveolar budding (Figure 2 A,B) . Evidence of abnormal ductal thickening was present in only 2/12 (17%) neu/VDR+/+ mice. In contrast, 100% of mammary glands from neu/VDR-/-mice exhibited major changes in ductal architecture characterized by extensive lobuloalveolar budding off primary ducts and stubby, dilated ducts ( Figure 2 G,H). In glands from neu/VDR+/-mice ( Figure 2 D,E), an intermediate phenotype was observed, with predominantly normal ductal architecture, but increased incidence of ductal thickening compared to neu/VDR+/+ mice. On histological examination, the thickened and dilated ducts in glands from both neu/VDR-/-and neu/VDR+/-mice showed evidence of secretions (Figures 2 E,H), whereas ducts of neu/VDR+/+ mice were empty ( Figure 2B ). The abnormal lobuloalveolar units branching off primary ducts in glands from neu/VDR-/-mice were acinar-like structures rather than solid dysplasias ( Figure  2H ).
While VDR status did not significantly alter the morphology of preneoplastic lesions (Figure 2 C,F,I), the incidence of pre-neoplastic lesions was 75% in glands from neu/VDR-/-and neu/VDR+/-mice compared to 50% in neu/VDR+/+ mice (Table I) .
VDR ablation impairs survival of MMTV-neu mice.
These initial data indicated that pre-neoplastic lesions were present in the majority of MMTV-neu mice by 10.5 months of age and that mammary gland morphology was altered in neu/VDR+/-and neu/VDR-/-females. Based on other studies in which neu-driven mammary tumorigenesis was studied on the C57BL6 background (35, 36) , we chose to monitor the remaining neu/VDR+/+, neu/VDR+/-and neu/VDR-/-mice up to 18.5 months of age.
During the long term follow-up, morbidity and mortality were unexpectedly observed in mice lacking VDR. Kaplan-Meier analysis of survival data ( Figure 3A) revealed that neu/VDR-/-mice exhibited significantly decreased survival compared to their neu/VDR+/+ and neu/VDR+/-littermates. Mean survival time for neu/VDR-/-mice was 11 months, compared to 15.5 months for neu/VDR+/+ mice and 15 months for neu/VDR+/-mice. Unlike neu/VDR+/+ and neu/VDR+/-mice, who died or were euthanized due to tumor burden, the majority of premature deaths in neu/VDR-/-mice were not attributable to mammary tumor development. Morbidity in neu/VDR-/-mice was associated with significantly lower body weight compared to either neu/VDR+/+ or neu/VDR+/-mice ( Figure 3B ), and abdominal fat stores were severely depleted in MMTV-neu mice with VDR ablation (not shown). Although poor survival in neu/VDR-/-mice was clearly related to VDR deficiency, the high calcium "rescue" diet was sufficient to maintain serum calcium within the normal range ( Figure 3C ), suggesting a cause other than disturbed calcium homeostasis to explain the increased morbidity in the neu/VDR-/-mice.
Analysis of tissues recovered from neu/VDR-/-mice older than one year clearly indicated that the adipose compartment of the mammary gland was severely atrophied in comparison to neu/VDR+/+ or neu/VDR+/-glands that showed a normal morphology, with large plump adipose tissue surrounding the mammary ducts and lymph node (Figure 4 A,B,C) . Despite atrophy of the mammary fat pad in aging neu/VDR-/-mice, whole mounts and histological analysis showed large distended ducts containing secretions and extensive alveolar hyperplasias evident in the neu/VDR-/-glands ( Figure  4 F,I ). Similar abnormal ductal morphology was observed in VDR-/-F 2 littermates that lacked neu transgene expression (Figure 4 , compare panels F and J), indicating that this effect is related to VDR insufficiency. In the majority of glands from aging neu/VDR-/-mice, one or more of the distended ducts contained dysplastic mammary epithelial cells ( Figure 4K ). Epithelial cells within these dysplastic areas were consistently positive for neu immunostaining ( Figure 4L, arrowhead) , whereas epithelial cells lining the dilated ducts did not express neu ( Figure 4L , arrows). Glands from age-matched neu/VDR+/-mice (which were not atrophied) also exhibited distended ducts, hyperplasia, and dysplastic cells (Figure 4 E,H), although the phenotype was not as severe as their neu/VDR-/-littermates. In contrast, hyperplasia and distended ducts were minimal in glands from neu/VDR+/+ mice ( Figure D,G) . These observations indicate that while mammary glands from neu/VDR+/+ and neu/VDR+/-mice displayed the typical epithelium:stromal content, mammary glands from neu/VDR-/-mice displayed abnormal ductal morphology, hyperplasia, and an ever increasing epithelium:stromal content which became more pronounced with age.
Since estrogen stimulates epithelial cell proliferation and induces the MMTV-neu promoter that drives neu expression in this model, and VDR ablation has been associated with impaired estrogen production (37), we measured circulating estrogen as a function of VDR status. Estrogen levels were not affected by VDR status in young mice, but decreased with age and were significantly lower in neu/VDR-/-mice than neu/VDR+/+ mice from 11.5 months on ( Figure 5 ).
VDR haploinsufficiency accelerates MMTV-neu driven mammary tumorigenesis.
Within the first year of observation, palpable mammary tumors developed in a stochastic manner for all three VDR genotypes of MMTV-neu mice. Time to detection of the first tumor was 8.5 months in neu/VDR+/+ mice, 7 months in neu/VDR+/-mice and 6 months in neu/VDR-/-mice, suggesting a possible inhibitory effect of VDR. By 12 months of age, tumor incidence was 19.1% in neu/VDR+/+ mice, 22.8% in neu/VDR+/-mice and 24.1% in neu/VDR-/-mice. As noted above, by 12 months of age, the majority of neu/VDR-/-mice died or were euthanized due to morbidity, and the remainder experienced significant weight loss. Despite poor overall health and shortened lifespan, 59% of neu/VDR-/-animals developed palpable mammary tumors. However, only one of 72 neu/VDR-/-mice completed the study, making it impossible to accurately assess the effect of VDR ablation on long term tumor development in these animals. Since haploinsufficiency of the VDR did not compromise body weight or survival, it was possible to compare long term tumor development in neu/VDR+/+ and neu/VDR+/-mice. Kaplan-Meier analysis ( Figure 6 ) indicated that mammary tumor development was significantly enhanced in neu/VDR+/-mice compared to neu/VDR+/+ mice, and this difference became apparent during the second year of observation. The time for 50% of neu/VDR+/-mice to develop tumors was 14.5 months of age compared to 18.5 months for neu/VDR+/+ mice (p<0.005). Furthermore, by 18.5 months of age, mammary tumors had developed in 74% of the neu/VDR+/-mice compared to 53% of the neu/VDR+/+ mice (p<0.005). The number of tumors per mouse tended to be higher in neu/VDR+/-mice (1.7) compared to neu/VDR-/-mice (1.5) and neu/VDR+/+ mice (1.3), however, these differences were not statistically significant. Data on tumor development for MMTV-neu mice of all three VDR genotypes are summarized in Table  I .
We also assessed the percentage of lung metastases to determine if tumors with differing VDR status varied in metastatic potential. However, in these MMTV-neu animals on the C57BL6 background, the incidence of lung metastases was only about 5%, and there was no effect of VDR status on the percentage of tumor bearing animals that developed lung metastasis.
Effect of VDR status on tumor histopathology, VDR and neu expression.
Representative tumors from neu/VDR+/+ and neu/VDR+/-mice at 16.5 months of age were assessed histologically ( Figure 7) . Tumors from six neu/VDR-/-mice that survived to 16.5 months of age were available for comparison, and a representative tumor is presented in Figure 7 . Regardless of VDR status, all tumors displayed the typical adenocarcinoma morphology characteristic of MMTV-neu induced tumors (38) and were well vascularized. There were no obvious morphological differences in tumor cellularity or epithelial:stromal ratio as a function of VDR ( Figure 7A,C,E) . Expression of c-neu was detected on the plasma membrane of the epithelial cells in all tumors (Figure  7 B,D,F) , and relative c-neu expression as detected by western blotting of homogenates from these tumors was similar in all three genotypes ( Figure 7G ).
Finally, we assessed whether the enhanced tumor development in neu/VDR+/-mice correlated with reduced tumor VDR expression (Figure 8 ). Mean steady state VDR mRNA, measured by quantitative real time PCR, was lower in tumors from neu/VDR+/-mice as compared to neu/VDR+/+ mice ( Figure 8A ), although this difference did not reach statistical significance (p = 0.17). Western blotting indicated that VDR protein expression was lower in mammary tumors, as well as kidney (a well characterized vitamin D 3 target tissue), derived from neu/VDR+/-mice as compared to neu/VDR+/+ mice ( Figure 8B ). Immunostaining indicated diffuse VDR expression throughout tumors from both neu/VDR+/+ mice and neu/VDR+/-mice, suggesting that complete loss of the remaining wild-type VDR allele in neu/VDR+/-mice was unlikely. As expected, no VDR mRNA or protein was detected in homogenates of mammary tumors or kidney from neu/VDR-/-mice.
DISCUSSION
In this study we have examined whether disrupted VDR signaling alters murine mammary gland morphology or transformation in response to the neu proto-oncogene. MMTV-neu mice overexpress c-neu in mammary gland (26) and mimic human breast cancers with amplification of erbB2, a member of the EGF receptor family. MMTV-neu mice were crossed with VDR-/-mice to generate mice with enhanced neu expression and altered VDR status. Two key conclusions can be drawn from these studies in which mammary gland pathology and tumor development were monitored for up to 18.5 months. The first major conclusion is that complete loss of VDR signaling results in pathological changes, including dysplasia of the mammary ductal epithelia and atrophy of the associated fat pad, in aging female neu/VDR-/-mice. VDR ablation also significantly reduces body weight and compromises long term survival despite dietary maintenance of normocalcemia. The second major conclusion is that haploinsufficiency of the VDR accelerates neu driven tumorigenesis (as supported by increased incidence and decreased latency of mammary tumors in neu/VDR+/-mice as compared to neu/VDR+/+ mice). Combined with previous findings that VDR ablation enhances chemically induced carcinogenesis in skin (39) and induces pre-malignant changes in colonic epithelium (40) , these data implicate the vitamin D 3 signaling pathway as a general suppressor of tumorigenesis.
The observation of ductal thickening, increased lesion development and accelerated onset of neu driven mammary tumors in mice heterozygous for the VDR provides the first evidence that VDR status affects mammary cancer development in vivo. We show that, in contrast to estrogen and progesterone receptors (which are not expressed in neu driven tumors) (41, 42) , VDR is highly expressed in early and late stage MMTV-neu mammary tumors as well as in pulmonary metastatic foci. Furthermore, VDR protein expression in tumors and tissues from neu/VDR+/-mice is reduced to about half that of neu/VDR+/+ littermates. Assuming that the VDR present in neu driven tumors is functional, our data suggests that VDR signaling is approximately two-fold lower in neu/VDR+/-mice compared to neu/VDR+/+ mice. Changes in VDR expression of this magnitude correlate with parallel changes in VDR mediated gene expression and biological effects both in vivo and in vitro (43) (44) (45) . 1,25(OH) 2 D 3 , the ligand for the VDR, is a negative growth regulator of both normal and transformed mammary epithelial cells (46) (47) (48) , and prevents the development of carcinogen induced preneoplastic lesions in mammary organ culture (17) . In addition, VDR agonists exert anti-tumor effects in animal models, and these effects are dependent on expression of functional VDRs in tumor cells (9, 34) . Although our studies do not rule out the possibility that VDR haploinsufficiency might impact on tumorigenesis secondary to decreased VDR in non-mammary tissues, the most likely basis for the enhanced tumorigenesis in neu/VDR+/-mice is reduced signaling through the VDR in the mammary gland.
The best characterized action of VDR is transcriptional regulation, but the vitamin D 3 regulated target genes in mammary gland relevant to tumorigenesis have yet to be identified. 1,25(OH) 2 D 3 inhibits signaling through the EGF family of receptors, including erbB-2, in MCF-7 breast cancer cells (49) . In the current study, VDR status did not alter expression of the neu transgene, but further studies are necessary to determine if neu tyrosine kinase activity is altered by VDR status. Other potential downstream VDR targets include tumor suppressor genes such as PTEN, p21 and p27 (50, 51, 48) . Interestingly, haploinsufficiency of PTEN or p27 increases tumorigenesis in animal models of prostate and breast cancer, respectively (52, 53, 36) . Similar to our findings with VDR, Muraoka et al (36) demonstrated that p27 +/-mice are more susceptible to MMTV-neu tumorigenesis than their p27 +/+ littermates. Our studies add the VDR to the list of genes that may act in a haploinsufficient manner to impact on tumorigenesis (53) .
The increased incidence of mammary tumors in mice heterozygous for the VDR would predict that complete loss of VDR would also be associated with accelerated tumorigenesis. Despite more extensive glandular hyperplasia and dysplasia in neu/VDR-/-mice compared to neu/VDR+/+ mice, the final tumor incidence in neu/-VDR-/-mice (59%) was only slightly higher than that in neu/VDR+/+ mice (53%). However, tumor incidence data in neu/VDR-/-mice should be interpreted with caution, since the majority of neu/VDR-/-animals experienced poor overall health, weight loss and mortality within the first year of the study, making accurate long term follow-up of tumor development in these animals complicated. This is particularly important since differences in tumor development between neu/VDR+/-mice and neu/VDR+/+ mice only became apparent in the second year of follow-up. The loss of body weight, atrophy of adipose stores and reduced circulating estrogen in neu/VDR-/-mice older than 12 months could theoretically have hindered the progression of early stage lesions into palpable mammary tumors and thus were confounding factors in this study. Although estrogen is not required for MMTV-neu tumorigenesis in post-pubertal animals (30), estrogen stimulates estrogen receptor positive stromal or epithelial cells to secrete growth factors required for the outgrowth of preneoplastic lesions into palpable tumors (54) (55) (56) . Therefore, the reduced circulating estrogen in older neu/VDR-/-mice could have altered the incidence or timing of tumor outgrowth. In addition, final tumor development in neu/VDR-/-mice was assessed in the presence of body weight loss and mammary fat pad atrophy. The adipose and stromal compartments of the gland facilitate tumorigenesis through release of diffusible growth factors that stimulate epithelial cell receptors including neu (54, 57, 58) and regulate production of extracellular matrix proteins (54, 58) . Thus, fat pad atrophy in older neu/VDR-/-mice could have prevented or delayed tumor outgrowth in comparison to neu/VDR+/+ and neu/VDR+/-littermates with abundant adipose tissue stores. A true analysis of the impact of VDR ablation on MMTV-neu tumorigenesis will require development of a mammary-specific VDR knockout animal model.
Another important outcome of this study is the observation that aging neu/VDR-/-females display altered mammary gland morphology including alveolar outgrowths and dilated ducts filled with secretory material. While alveolar outgrowths in neu/VDR-/-mice correlated with neu expression, epithelial cells within the dilated ducts were uniformly negative for neu transgene expression. Furthermore, age-matched female VDR-/-littermates from the F2 generation that were negative for transgene expression displayed fat pad atrophy and dilated ducts without alveolar outgrowths. This suggests that the abnormal ductal morphology in neu/VDR-/-females is secondary to VDR insufficiency rather than neu signaling. In support of this suggestion, aging female virgin mice in our VDR-/-colony on the C57BL background develop similar ductal morphology which is associated with inappropriate casein expression (Zinser and Welsh, unpublished) , and ongoing studies are directed at characterizing this phenotype more completely.
The mechanisms underlying the systemic wasting and shortened lifespan of neu/VDR-/-animals, reported here for the first time, remain to be elucidated. Neither phenotype was related to hypocalcemia, since the high calcium diet maintained extracellular calcium homeostasis in the neu/VDR-/-mice during the extended period of this study. Weight loss and reduced lifespan were not correlated with neu expression, since survival was also compromised (mean survival 11.6 months) in a cohort of 15 VDR-/-F 2 littermates generated in this study that lacked neu transgene expression. Furthermore, we have observed atrophy of abdominal fat stores, weight loss and reduced survival in our non-transgenic VDR knockout colony maintained on the C57BL background. Poor survival could have been related to alopecia, dermal cyst formation and thickened wrinkled skin which is characteristic of VDR ablation and can precipitate infections (59, 60, 39) . VDR ablation may also directly affect adipose tissue since the VDR is highly induced during adipocyte differentiation and 1,25(OH) 2 D 3 regulates expression of genes such as leptin and uncoupling protein which participate in energy balance (61) (62) (63) (64) . Therefore VDR ablation may interfere with turnover of adipose tissue, which could affect both longevity and mammary gland biology. However, since adipose tissue appears normal in young neu/VDR-/-mice, further studies are required to identify factors that might precipitate atrophy of the adipose tissue during aging of neu/VDR-/-mice.
In summary, the studies reported here demonstrate that disruption of VDR signaling induces mammary gland pathology and accelerates breast cancer development in MMTV-neu transgenic mice, a model that mimics her2/neu positive human breast cancer. Since the ligand for VDR is derived from vitamin D 3 , an important implication of these studies, which is currently being tested in our laboratory, is that optimal vitamin D 3 status will prevent or delay neu driven mammary tumorigenesis. No differences in morphology or c-neu staining were detected as a function of VDR status. Scale bar, 50uM. G. Western blot for c-neu in tumors from neu/VDR+/+, neu/VDR+/-and neu/VDR-/-mice. Tumor homogenates were separated by SDS-PAGE, transferred to nitrocellulose and incubated with antibody against c-neu. Blot shows two independent tumor homogenates from both neu/VDR+/+ and neu/VDR+/-mice and one homogenate from neu/VDR-/-mouse. Kidney was used as a negative control for transgene expression. Ductal pathology and preneoplastic lesions were evaluated in whole mounts from twelve MMTV-neu mice of each genotype (neu/VDR+/+, neu/VDR+/-and neu/VDR-/-) at 10.5 months of age. Animals were considered positive for pre-neoplastic lesions if at least one gland (of four examined) contained a pre-neoplastic lesion as defined in Materials and Methods. Animals were considered positive for ductal thickening if at least one gland contained two or more areas of generalized thickening and dilation of ducts. Statistical evaluation was by Fisher's exact test. Data on tumor incidence, multiplicity and latency were statistically evaluated by Kaplan Meier analysis or Fisher's exact test. *Significantly (p<0.05) different, neu/VDR+/-or neu/VDR-/-vs. neu/VDR+/+. 
